The revised provisions provide medical device and in-vitro diagnostics manufacturers with additional time to bring their product into compliance with the new EU Regulations, subject to a number of conditions.
On March 20,...more
The response includes a considered implementation plan to strengthen the regulation of medical devices and in vitro diagnostics, improve patient safety, and foster innovation post-Brexit.
On 26 June 2022, the UK Medicines...more
7/1/2022
/ Consultation ,
Diagnostic Tests ,
Life Sciences ,
Medical Devices ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
Pharmaceutical Industry ,
Proposed Regulation ,
Public Comment ,
Public Health ,
Technology ,
UK ,
UK Brexit